3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Breast Neoplasms
17
Neoplasms
16
Multiple Myeloma
16
Leukemia, Myeloid, Acute
15
Recurrence
10
Colorectal Neoplasms
10
Myelodysplastic Syndromes
9
Lymphoma, Non-Hodgkin
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Melanoma
7
Lymphoma, Follicular
7
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
7
Stomach Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Uterine Cervical Neoplasms
5
Purpura, Thrombocytopenic, Idiopathic
5
Neoplasm Metastasis
5
Lymphoma, Mantle-Cell
5
Lung Neoplasms
5
Graft vs Host Disease
5
Esophageal Neoplasms
5
Bronchiolitis Obliterans Syndrome
5
Adenocarcinoma
5
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA